Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
1225
mi
from 91732
Dallas, TX
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
University of Texas Medical Branch
1399
mi
from 91732
Galveston, TX
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
University of Texas Medical Branch
1399
mi
from 91732
Galveston, TX
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
M. D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
M. D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
565
mi
from 91732
Murray, UT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
565
mi
from 91732
Murray, UT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Utah Valley Regional Medical Center - Provo
553
mi
from 91732
Provo, UT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Utah Valley Regional Medical Center - Provo
553
mi
from 91732
Provo, UT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Dixie Regional Medical Center - East Campus
325
mi
from 91732
Saint George, UT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Dixie Regional Medical Center - East Campus
325
mi
from 91732
Saint George, UT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
CCOP - Virginia Mason Research Center
961
mi
from 91732
Seattle, WA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
CCOP - Virginia Mason Research Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
University Cancer Center at University of Washington Medical Center
943
mi
from 91732
Seattle, WA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
University Cancer Center at University of Washington Medical Center
943
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Legacy Salmon Creek Medical Center
840
mi
from 91732
Vancouver, WA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Legacy Salmon Creek Medical Center
840
mi
from 91732
Vancouver, WA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Theda Care Cancer Institute
1723
mi
from 91732
Appleton, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Theda Care Cancer Institute
1723
mi
from 91732
Appleton, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic Cancer Care at Regional Cancer Center
1587
mi
from 91732
Eau Claire, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic Cancer Care at Regional Cancer Center
1587
mi
from 91732
Eau Claire, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Vincent Hospital Regional Cancer Center
1745
mi
from 91732
Green Bay, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Vincent Hospital Regional Cancer Center
1745
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Gundersen Lutheran Center for Cancer and Blood
1578
mi
from 91732
La Crosse, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Gundersen Lutheran Center for Cancer and Blood
1578
mi
from 91732
La Crosse, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic - Marshfield Center
1645
mi
from 91732
Marshfield, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic - Marshfield Center
1645
mi
from 91732
Marshfield, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Saint Joseph's Hospital
1645
mi
from 91732
Marshfield, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Saint Joseph's Hospital
1645
mi
from 91732
Marshfield, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Columbia Saint Mary's Hospital - Ozaukee
1726
mi
from 91732
Mequon, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Columbia Saint Mary's Hospital - Ozaukee
1726
mi
from 91732
Mequon, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Columbia-Saint Mary's Cancer Care Center
1730
mi
from 91732
Milwaukee, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Columbia-Saint Mary's Cancer Care Center
1730
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Medical College of Wisconsin Cancer Center
1722
mi
from 91732
Milwaukee, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Medical College of Wisconsin Cancer Center
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic - Lakeland Center
1693
mi
from 91732
Minocqua, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic - Lakeland Center
1693
mi
from 91732
Minocqua, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Ministry Medical Group at Saint Mary's Hospital
1702
mi
from 91732
Rhinelander, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Ministry Medical Group at Saint Mary's Hospital
1702
mi
from 91732
Rhinelander, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic - Indianhead Center
1592
mi
from 91732
Rice Lake, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic - Indianhead Center
1592
mi
from 91732
Rice Lake, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic at Saint Michael's Hospital
1671
mi
from 91732
Stevens Point, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic at Saint Michael's Hospital
1671
mi
from 91732
Stevens Point, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Waukesha Memorial Hospital Regional Cancer Center
1710
mi
from 91732
Waukesha, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Waukesha Memorial Hospital Regional Cancer Center
1710
mi
from 91732
Waukesha, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Diagnostic and Treatment Center
1678
mi
from 91732
Weston, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Diagnostic and Treatment Center
1678
mi
from 91732
Weston, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Marshfield Clinic - Weston Center
1678
mi
from 91732
Weston, WI
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Marshfield Clinic - Weston Center
1678
mi
from 91732
Weston, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Regions Hospital - Cancer Care Center
1517
mi
from 91732
Saint Paul, MN
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Regions Hospital - Cancer Care Center
1517
mi
from 91732
Saint Paul, MN
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Billings Clinic - Downtown
948
mi
from 91732
Billings, MT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Billings Clinic - Downtown
948
mi
from 91732
Billings, MT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
1316
mi
from 91732
Sioux Falls, SD
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Sanford Cancer Center at Sanford USD Medical Center
1316
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
26
mi
from 91732
Santa Monica, CA
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
26
mi
from 91732
Santa Monica, CA
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2462
mi
from 91732
Norwalk, CT
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2462
mi
from 91732
Norwalk, CT
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2410
mi
from 91732
New Brunswick, NJ
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2410
mi
from 91732
New Brunswick, NJ
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Greenville Hospital System
2023
mi
from 91732
Greenville, SC
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Greenville Hospital System
2023
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2019
mi
from 91732
Greenville, SC
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2019
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Research Site
mi
from 91732
Lyon CEDEX 08,
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Research Site
mi
from 91732
Lyon CEDEX 08,
Click here to add this to my saved trials
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
2430
mi
from 91732
Hackensack, NJ
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
Stanford Cancer Institute
328
mi
from 91732
Stanford, CA
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
Stanford Cancer Institute
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
University of Chicago
1730
mi
from 91732
Chicago, IL
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
University of Chicago
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
South Texas Accelerated Research Therapeutics (START)-Midwest
1839
mi
from 91732
Grand Rapids, MI
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
South Texas Accelerated Research Therapeutics (START)-Midwest
1839
mi
from 91732
Grand Rapids, MI
Click here to add this to my saved trials
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated:  12/13/2017
South Texas Accelerated Research Therapeutics
1182
mi
from 91732
San Antonio, TX
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status: Enrolling
Updated: 12/13/2017
South Texas Accelerated Research Therapeutics
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma
Status: Enrolling
Updated:  12/18/2017
Burzynski Clinic
1348
mi
from 91732
Houston, TX
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma
Status: Enrolling
Updated: 12/18/2017
Burzynski Clinic
1348
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
Status: Enrolling
Updated:  12/18/2017
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center
2434
mi
from 91732
New York, NY
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
Status: Enrolling
Updated: 12/18/2017
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/19/2017
CCOP - Christiana Care Health Services
2347
mi
from 91732
Newark, DE
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/19/2017
CCOP - Christiana Care Health Services
2347
mi
from 91732
Newark, DE
Click here to add this to my saved trials